Market Conditions and Cost Pressures are Prompting Redesign of Manufacturing Facilities
This article was originally published in The Gold Sheet
The pharmaceutical and biotech manufacturing facilities of the future will be smaller and simpler than existing facilities, have more closed processes, combine clinical and commercial operations under one roof, and use more disposable equipment. Cost pressures and market conditions are behind some of these anticipated changes, some of which are occurring right now.
You may also be interested in...
Although compounding of certain shortage drugs is allowed during the public health emergency, remdesivir is off limits due to its complexity. Providers should only use the FDA-approved version of the drug, Gilead’s Veklury, the agency says.
Drug makers win one-month reprieve for their nitrosamine risk assessments for new drug products and approved products.
Technologies like head-mounted tablets became critical for method transfers, virtual inspections and more. Cloud-based submissions could be next …